CTLA4 and melanoma: Such developments led to the first US FDA-approved immune checkpoint inhibitor (ICI), ipilimumab—a cytotoxic T-lymphocyte antigen-4 (CTLA-4)-targeting monoclonal Ab—for the treatment of patients with advanced melanoma [1].